title: Tardive dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use.
abstract: Atypical antipsychotic medications are commonly used in large-scale residential care facilities for adults with developmental disabilities. While the benefits of this class of psychotropics are noted, debate exists whether the side effect profile of these medications outweigh their therapeutic benefit, especially in those who use them long-term. Tardive Dyskinesia (TD) is a movement disorder often caused by a history of neuroleptic use which can cause deleterious effects. Due to the seriousness of TD and the impact on an individual's quality of life, it is necessary to identify predisposing factors for this condition in a population of adults with intellectual and developmental disabilities. The current study seeks to expand the literature related to TD and atypical antipsychotic medication utilizing a measure of medication side effects, the Matson Evaluation of Drug Side Effects (MEDS). Results and implications for assessment and practice are discussed.
authors.affiliation: Louisiana State University, Baton Rouge, LA 70803, United States.
authors.forename: Jill C
authors.initials: JC
authors.lastname: Fodstad
authors.forename: Jay W
authors.initials: JW
authors.lastname: Bamburg
authors.forename: Johnny L
authors.initials: JL
authors.lastname: Matson
authors.forename: Sara
authors.initials: S
authors.lastname: Mahan
authors.forename: Julie A
authors.initials: JA
authors.lastname: Hess
authors.forename: Daniene
authors.initials: D
authors.lastname: Neal
authors.forename: Jodie
authors.initials: J
authors.lastname: Holloway
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology; D003866:Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D011619:Psychotropic Drugs / Q000009:adverse effects; D012112:Residential Facilities / Q000706:statistics & numerical data; D012307:Risk Factors; D012720:Severity of Illness Index; D019956:Stereotypic Movement Disorder / Q000188:drug therapy / Q000453:epidemiology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D011619:Psychotropic Drugs